Banerjee Subhashis, the Chief Medical Officer of Artiva Biotherapeutics, Inc., recently sold 1,110 shares of the company’s common stock. This transaction occurred on November 2, 2026, and was reported to the SEC on November 3, 2026. The sale was made to cover tax obligations related to the vesting of restricted stock units.

The sale is part of a 'sell-to-cover' policy adopted by Artiva Biotherapeutics. This policy allows executives to automatically sell a portion of their shares to meet tax withholding obligations. Such transactions are common in the life sciences sector, particularly among executives managing their stock holdings.

Background

Artiva Biotherapeutics, Inc. is classified under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company is based in San Diego, California, and is focused on advancing innovative therapies in the life sciences field. The recent filing is part of a series of Form 4 submissions by Banerjee Subhashis, indicating ongoing activity in managing his equity stake in the company.

What the Filing Says

The SEC filing indicates that the shares were sold at a price of $4.1811 each. Following the transaction, Banerjee Subhashis holds a total of 168,738 shares. The filing also clarifies that these sales were automatic and not at the discretion of the reporting person.

Impact

This transaction may influence perceptions of executive management within Artiva Biotherapeutics, as such sales are typically scrutinized by investors and analysts. However, the automatic nature of the sale under the 'sell-to-cover' policy suggests that it is a routine financial management decision rather than a signal of the company’s performance.

What's Next

The filing does not say what happens next regarding further transactions or changes in executive management.